Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: Protocol for a Diagnostic Accuracy Study

RecruitingOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Myelodysplastic Syndromes
Interventions
DIAGNOSTIC_TEST

Flow cytometric analysis of neutrophil myeloperoxidase expression

"Performance of flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed on the same day of collection.~Blood samples will be incubated with a panel of antibodies conjugated to fluorochromes, according to the manufacturers' recommendations.~At least 10,000 cell events will be acquired on a 3-laser, 8/12-color flow cytometer and analyzed using flow cytometry software. Myeloperoxidase expression in the peripheral blood neutrophil population within an individual subject will be expressed as intra-individual robust coefficient of variation (RCV)."

Trial Locations (8)

13009

RECRUITING

Institut Paoli Calmettes, Marseille

34090

RECRUITING

University Hospital Saint-Eloi, Montpellier

38043

RECRUITING

Grenoble_Alpes UniversityHospital, Grenoble

42055

RECRUITING

University Hospital, Saint-Étienne, Saint-Etienne

44093

RECRUITING

Chu Nantes, Nantes

63003

NOT_YET_RECRUITING

University Hospital, Clermont-Ferrand, Clermont-Ferrand

69310

RECRUITING

University Hospital Lyon Sud, HCL, Lyon

06202

RECRUITING

University Hospital NICE, Nice

All Listed Sponsors
lead

University Hospital, Grenoble

OTHER

NCT05175469 - Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: Protocol for a Diagnostic Accuracy Study | Biotech Hunter | Biotech Hunter